Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
RAPT Therapeutics, Inc. files post-effective amendments to deregister all unsold securities under Registration Statements No. 333-273910 and No. 333-284388 after the closing of a merger.
The amendments state that pursuant to the Agreement and Plan of Merger dated January 19, 2026, effective March 3, 2026, RAPT merged into a GlaxoSmithKline affiliate and is now a wholly owned subsidiary; offerings under those registration statements have been terminated and the unsold securities removed from registration.
RAPT Therapeutics has filed post-effective amendments to its Form S-3 registration statements Registration No. 333-273910 and Registration No. 333-284388 to deregister any securities that remained unsold as of March 3, 2026. The company states that, pursuant to the Agreement and Plan of Merger dated January 19, 2026, Merger Sub merged with and into the registrant and the registrant became a wholly owned subsidiary of GlaxoSmithKline LLC. As a result, the registrant terminated offerings under those registration statements and removed all unsold securities from registration, so there will be no remaining securities registered under those registration statements.
RAPT Therapeutics, Inc. notified Nasdaq Stock Market LLC of the voluntary removal of its Common Stock from listing and registration.
The notification states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing withdrawal and delisting; the filing is signed by a Nasdaq representative.
RAPT Therapeutics, Inc. has been acquired by GlaxoSmithKline through a cash tender offer followed by a merger under Delaware law. GSK’s subsidiary purchased all outstanding RAPT common shares at $58.00 per share in cash, and approximately 30,137,567 shares, or 93.36% of outstanding shares, were validly tendered.
After completing the offer, GSK merged its acquisition vehicle into RAPT, making RAPT a direct wholly owned subsidiary. RAPT’s Nasdaq-listed common stock will be halted, delisted and deregistered, and the company plans to terminate its SEC reporting obligations. RAPT’s prior directors and officers resigned, and new GSK-affiliated officers and directors were appointed.
RAPT Therapeutics filed Amendment No. 2 to its Schedule 14D-9 reporting final results of the tender offer by an affiliate of GSK. The Offer at $58.00 per share expired on March 2, 2026, with 30,137,567 Shares validly tendered, representing 93.36% of issued and outstanding Shares as of the Expiration Time. The filing states the Minimum Condition was satisfied, Purchaser accepted for payment the Shares, and the Company expects Parent to complete the merger on March 3, 2026, after which the Shares will be delisted and registration and reporting under the Exchange Act will be terminated.
RAPT Therapeutics was acquired via a completed tender offer by Redrose Acquisition Co., GlaxoSmithKline LLC and GSK plc for $58.00 per share. The offer expired at one minute after 11:59 P.M. Eastern on March 2, 2026, and 30,137,567 Shares were validly tendered, representing 93.36% of issued and outstanding Shares as of that time.
Because the Minimum Condition was satisfied, Purchaser accepted the tendered Shares and will pay for them promptly. Under Section 251(h) of the DGCL, Ultimate Parent, Parent and Purchaser intend to effect the Merger without a stockholder meeting, delist the Shares from Nasdaq, and take steps to terminate registration and suspend reporting as promptly as practicable.
RAPT Therapeutics, Inc. is the subject of an all‑cash tender offer by Redrose Acquisition Co., an entity controlled by GlaxoSmithKline, to acquire all outstanding common shares for $58.00 per share.
The filing states the Hart‑Scott‑Rodino waiting period expired February 23, 2026 and the "Regulatory Conditions to the Offer have been satisfied." The filing also reports that, as of February 24, 2026, two state‑court complaints were filed (Morgan and Walsh) alleging negligent misrepresentation and concealment related to the Schedule 14D‑9, and the Company received twelve demand letters alleging disclosure deficiencies.
RAPT Therapeutics, Inc. amended its Schedule 14D-9 to supplement disclosures about the tender offer by a GlaxoSmithKline affiliate to acquire all outstanding common shares for $58.00 per share in cash.
The amendment adds background on a prior $50.00 per‑share proposal from GSK on December 22, 2025, J.P. Morgan’s discounted cash flow implied equity range of $49.45 to $62.05 per share, a precedent‑premium reference range of approximately $50.95 to $73.40 per share, analyst target references (low/high $56.00 to $95.00), and disclosure that J.P. Morgan’s aggregate fee is estimated at $50.4 million. The filing also states the HSR waiting period expired effective February 23, 2026, and notes two complaints and twelve demand letters challenging disclosure; the Company denies those claims.